Goncalves, Isaac
Burbury, Kate
Michael, Michael
Iravani, Amir
Ravi Kumar, Aravind S.
Akhurst, Tim
Tiong, Ing S.
Blombery, Piers
Hofman, Michael S.
Westerman, David
Hicks, Rodney J.
Kong, Grace
Article History
Received: 11 March 2019
Accepted: 31 May 2019
First Online: 11 June 2019
Compliance with ethical standards
:
: RJH holds shares in Telix Pharmaceuticals on behalf of the Peter MacCallum Cancer Centre. MSH reports personal fees and non-financial support from Ipsen and Sanofi Genzyme, personal fees and other from Endocyte, outside the submitted work. All remaining authors declare no competing interests.
: The study was approved by the Peter MacCallum Cancer Centre ethics committee as a retrospective audit with approval of waiver for patient consent (HREC Project number 18/61R). All patients had previously provided written, informed consent for PRRT/PRCRT under existing compassionate use guidelines. This article does not contain any studies with human participants or animals performed by any of the authors.